Sir,
We would like to thank Daniel B Costa, MD for his interest in our manuscript.
In his letter, Dr Costa cited the two retrospective studies (Riely et al, 2006; Jackman et al, 2006) showing prolonged time to progression and overall survival (OS) of non-small cell lung cancer patients with exon 19 deletions when compared with L858R patients given epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors, and raised the important issue of clinical differences between these two types of mutations. As Dr Costa also mentioned, however, the two Japanese prospective trials (including our own) have shown no significant differences in response rate between these mutation types (Asahina et al, 2006; Inoue et al, 2006). In our trial, where individual data for progression-free survival (PFS) and OS were available, median PFS for exon 19 deletion was 8.3 months and two of the three patients with L858R mutation were alive and progression-free after more than 11.7 months, whereas median OS has not been reached in either group.
The lack of observed higher efficacy against exon 19 deletions compared with L858R mutations in the Japanese trials may be due to insufficient numbers of patients, as these Japanese trials were not designed to determine differences in EGFR genotypes. However, the conflicting results could also reflect ethnic differences. In addition to our tials, we calculated median PFS for each type of mutation from the retrospective data provided by Chou et al (2005) and Zhang et al (2005), as both studies were conducted in East Asian countries. Median PFS was 7.8 months in patients with exon 19 deletions and 7.6 months in patients with L858R in the former study, and 6.4 months and 10.2 months in the latter study, respectively. Although we could not calculate precise OS from those data, median PFS of patients with L858R seemed similar to or longer than that for patients with exon 19 deletions in the East Asian studies.
Conflicting results are thus apparent regarding differences in these two mutations and further data collection is required. Differences in tyrosine phosphorylation status reported from the in vitro study by Chen et al (2006) suggest the existence of clinical differences between patients with these two mutations. We hope that subsequent randomised phase III trials in different ethnic populations will answer this question.
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Asahina H, Yamazaki K, Kinoshita I, Sukoh N, Harada M, Yokouchi H, Ishida T, Ogura S, Kojima T, Okamoto Y, Fujita Y, Dosaka-Akita H, Isobe H, Nishimura M (2006) A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 95: 998–1004
Chen YR, Fu YN, Lin CH, Yang ST, Hu SF, Chen YT, Tsai SF, Huang SF (2006) Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants. Oncogene 23: 1205–1215
Chou TY, Chiu CH, Li LH, Hsiao CY, Tzen CY, Chang KT, Chen YM, Perng RP, Tsai SF, Tsai CM (2005) Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 11: 3750–3757
Inoue A, Suzuki T, Fukuhara T, Maemondo M, Kimura Y, Morikawa N, Watanabe H, Saijo Y, Nukiwa T (2006) Prospective phase II study of gefitinib for chemotherapy-naïve patients with advanced non-small cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 24: 3340–3346
Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, Janne PA (2006) Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 12: 3908–3914
Riely GJ, Pao Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES, Zakowski MF, Kris MG, Ladanyi M, Miller VA (2006) Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 12: 839–844
Zhang XT, Li LY, Mu XL, Cui QC, Chang XY, Song W, Wang SL, Wang MZ, Zhong W, Zhang L (2005) The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer. Ann Oncol 16: 1334–1342
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Asahina, H., Yamazaki, K. & Kinoshita, I. Reply: Appropriate prospective trials are warranted to determine differences between exon 19 deletions and L858R EGFR mutations in non-small cell lung cancer. Br J Cancer 96, 400 (2007). https://doi.org/10.1038/sj.bjc.6603565
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6603565